How soon after the last Androver tablet should post-cycle therapy begin?

PCT can begin within 24–48 hours of the final Androver dose. Because Oxymetholone's plasma elimination is complete within approximately 36–45 hours, SERM agents such as Tamoxifen or Clomiphene can be introduced almost immediately — unlike long-ester injectables that require a multi-week washout delay before gonadotropin-stimulating therapy becomes pharmacologically rational.

Which PCT medications are considered evidence-supported after an Oxymetholone cycle?

SERMs — specifically Tamoxifen at 20–40 mg per day and Clomiphene at 50 mg per day — are the primary evidence-supported options. Both act at the pituitary to displace negative feedback and restore LH and FSH secretion. hCG may be introduced during the final cycle week to prime Leydig cell responsiveness before the SERM phase begins, particularly after cycles exceeding four weeks.

How long does HPG axis recovery typically take after stopping Androver?

HPG axis recovery duration varies by individual exposure history, but most users see measurable LH and FSH recovery within four to six weeks of structured SERM-based PCT, confirmed by serial serum assay. Cycle length and total cumulative milligrams of Oxymetholone consumed are the two strongest predictors of recovery timeline; longer or higher-dose cycles extend the suppression window and may require extended PCT.

Does the 50 mg per tablet concentration of Androver make it easier to plan PCT timing?

Yes — at 50 mg per tablet, the highest single-unit concentration in this compound's product group, each dose is a precisely defined androgenic increment with no splitting required. This makes it straightforward to calculate total cumulative milligrams consumed across the cycle, which directly informs PCT onset timing and SERM dose selection based on the depth and duration of HPG suppression anticipated.

Can Androver tablets be stored and counted accurately across a full cycle and PCT planning period?

The 100-tablet jar format allows straightforward tablet counting throughout the cycle, giving the user a real-time visual of remaining supply and making it easy to set a firm end date before PCT begins. Tablets should be stored at room temperature away from moisture and direct light; Vermodje's blister-sealed production process maintains API stability through the declared shelf life, so tablets remain within specification when stored correctly. (2) angle_used

High Concentration

Vermodje

Androver 50mg/tab 100 Tabletten by Vermodje

Name: Androver 50mg/tab 100 Tablets by Vermodje
Brand: Vermodje
SKU: ORA-OXYM-VER-022
Price: 42.00 EUR
Availability: InStock

Androver is an oral Oxymetholone tablet formulated at 50 mg per unit across a 100-tablet supply, engineered by Vermodje SRL with post-cycle therapy planning as the governing framework for safe and structured use. Each tablet delivers the full reference androgenic dose as a single analytically verified unit, making it straightforward to calculate cumulative exposure before PCT begins. Androver's release specification is validated through per-batch HPLC content-uniformity assay and LAL endotoxin screening at Vermodje's Chișinău facility — a compound-specific quality architecture applied independently to the tablet compression line.

€42.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Delivers a full 50 mg dose per tablet with no splitting or approximation required for PCT-mapped cycle planning.
100-tablet pack provides sufficient supply depth to complete a defined cycle plus retain documented end-date clarity for PCT onset.
HPLC content-uniformity verification at Vermodje's Chișinău facility confirms that cumulative exposure calculations used in PCT planning are based on accurate per-tablet API content.
Oxymetholone's rapid plasma clearance — within approximately 36–45 hours — allows PCT to begin almost immediately after the final dose, shortening the suppression window.
LAL endotoxin screening on incoming API ensures that the tablet matrix introduces no contaminating variables that could confound post-cycle liver enzyme interpretation.
Compact tablet form allows straightforward counting throughout the cycle, enabling precise identification of the final-dose day and PCT start date.

Phase	dosage	Note
Induction	25–50 mg/day	Weeks 1–2: establish baseline liver enzymes (ALT/AST) before full exposure; sets cumulative milestone for PCT start-date calculation.
Active Phase	50 mg/day	Weeks 3–4: peak androgenic output; track total cumulative milligrams to define suppression depth informing SERM dose selection.
Exit/Taper	25 mg/day	Final 3–5 days: step-down before cessation; last tablet day marks PCT Day 0 countdown.
PCT – SERM Induction	Tamoxifen 40 mg/day or Clomiphene 50 mg/day	Days 1–14 post-last Androver tablet; begins within 24–48 hours of cessation due to rapid Oxymetholone clearance.
PCT – SERM Maintenance	Tamoxifen 20 mg/day or Clomiphene 25 mg/day	Days 15–28: maintain gonadotropin stimulation; draw serum LH, FSH, testosterone at week 4 to confirm HPG recovery trajectory.

Key takeaways

Start PCT within 48 hours of the final Androver dose.
Use SERM agents — Tamoxifen or Clomiphene — to restart LH and FSH production.
Confirm HPG axis recovery with serial serum assay at PCT weeks two and four.
Calculate total cycle milligrams using the exact 50 mg per tablet concentration.
Monitor ALT and AST through the full PCT window, not only during the cycle.

Androver and Post-Cycle Therapy: The Recovery Framework Every User Must Plan Before Cycle Onset

Androver by Vermodje delivers Oxymetholone at 50 mg per tablet across a 100-unit pack, and its correct use is inseparable from a structured post-cycle therapy plan established before the first tablet is taken. PCT is the pharmacological bridge between the end of exogenous androgen exposure and the restoration of endogenous hypothalamic-pituitary-gonadal (HPG) axis function. Oxymetholone suppresses gonadotropin release — LH and FSH — through negative feedback at the hypothalamus and pituitary, a suppression documented by serum assay within the first two weeks of administration at 50 mg per day.

When to Begin PCT and Which Agents Apply

PCT timing is determined by the compound's elimination profile: because Oxymetholone clears the plasma within approximately 36–45 hours of the final dose based on its known half-life, PCT agents can be introduced within 24–48 hours of the last Androver tablet rather than the multi-week delay required after long-ester injectables. Selective oestrogen receptor modulators (SERMs) — primarily Tamoxifen at 20–40 mg per day and Clomiphene at 50 mg per day — are the evidence-supported pharmacological tools for restarting gonadotropin pulsatility, acting at the pituitary to displace negative feedback and restore FSH and LH secretion. Compared to aromatase inhibitor monotherapy used for the same purpose, SERM-based PCT produces faster measurable LH pulse recovery as assessed by serial serum assay.

Duration, Monitoring, and the Role of Bloodwork

Androver's 100-tablet count supports a complete structured cycle — including a conservative induction phase and a defined exit point — that maps directly to a four-to-six-week SERM-based recovery window. Recovery duration is not fixed: serum testosterone, LH, FSH, and ALT/AST panels drawn at week two and week four of PCT determine whether the HPG axis is recovering on trajectory or whether the SERM protocol requires extension. Vermodje's per-batch HPLC content verification means each 50 mg Androver tablet delivers a precisely accounted androgenic load, making cumulative exposure calculable and PCT onset plannable without approximation. Users must not skip the post-PCT bloodwork draw, as residual hepatic enzyme elevation — measured by ALT and AST — can persist beyond clinical symptoms and requires confirmation of normalisation before subsequent cycles are considered.

Usage

Before taking the first tablet, establish baseline bloodwork: serum testosterone, LH, FSH, ALT, and AST. These values form the reference against which PCT efficacy will be measured.
Take each 50 mg Androver tablet orally with water, ideally with a small meal to support gastric tolerance, and log the date of every dose to maintain an accurate cumulative milligram record.
At week two of the cycle, repeat ALT and AST panels; use results to confirm hepatic tolerance before continuing and to update your cumulative exposure calculation.
Identify your final-dose day in advance — before starting — so PCT agents (Tamoxifen or Clomiphene) are sourced and on hand before you need them; do not plan PCT retroactively.
Take the last Androver tablet and begin PCT within 24–48 hours; the short elimination window of Oxymetholone makes delayed PCT start a missed recovery window, not a conservative choice.
Draw a full panel — testosterone, LH, FSH, ALT, AST — at PCT weeks two and four to confirm HPG axis recovery is on trajectory; extend SERM therapy by two additional weeks if LH and FSH remain suppressed at the week-four draw.

Warnings

Contraindications: Androver is contraindicated in individuals with active hepatic disease, elevated bilirubin, prostate or breast carcinoma, pregnancy, and known hypersensitivity to Oxymetholone or any excipient in the tablet matrix. Do not use if baseline ALT or AST exceeds twice the upper reference limit before cycle onset.

Side Effects: Hepatotoxicity is the primary risk: ALT and AST elevation is expected and requires monitoring rather than tolerance. Additional effects include haematocrit increase, HDL suppression, LDL elevation, oedema, and HPG axis suppression that persists into the post-cycle window and is the direct rationale for structured SERM-based PCT.

Monitoring: Obtain liver enzyme panels (ALT, AST, bilirubin) and a full lipid profile at baseline, cycle week two, and within one week of the final dose. Repeat the panel at PCT week four to confirm hepatic normalisation. Any ALT or AST reading exceeding three times the upper reference limit during the cycle requires immediate cessation rather than dose adjustment.

PCT: Structured SERM-based PCT is mandatory after every Androver cycle. Tamoxifen at 20–40 mg per day or Clomiphene at 50 mg per day for a minimum of four weeks represents the evidence-supported standard. Serum testosterone, LH, and FSH confirmation of HPG recovery is required before concluding PCT; do not terminate SERM therapy based on subjective wellbeing alone.

Frequently asked questions

How soon after the last Androver tablet should post-cycle therapy begin?: PCT can begin within 24–48 hours of the final Androver dose. Because Oxymetholone's plasma elimination is complete within approximately 36–45 hours, SERM agents such as Tamoxifen or Clomiphene can be introduced almost immediately — unlike long-ester injectables that require a multi-week washout delay before gonadotropin-stimulating therapy becomes pharmacologically rational.
Which PCT medications are considered evidence-supported after an Oxymetholone cycle?: SERMs — specifically Tamoxifen at 20–40 mg per day and Clomiphene at 50 mg per day — are the primary evidence-supported options. Both act at the pituitary to displace negative feedback and restore LH and FSH secretion. hCG may be introduced during the final cycle week to prime Leydig cell responsiveness before the SERM phase begins, particularly after cycles exceeding four weeks.
How long does HPG axis recovery typically take after stopping Androver?: HPG axis recovery duration varies by individual exposure history, but most users see measurable LH and FSH recovery within four to six weeks of structured SERM-based PCT, confirmed by serial serum assay. Cycle length and total cumulative milligrams of Oxymetholone consumed are the two strongest predictors of recovery timeline; longer or higher-dose cycles extend the suppression window and may require extended PCT.
Does the 50 mg per tablet concentration of Androver make it easier to plan PCT timing?: Yes — at 50 mg per tablet, the highest single-unit concentration in this compound's product group, each dose is a precisely defined androgenic increment with no splitting required. This makes it straightforward to calculate total cumulative milligrams consumed across the cycle, which directly informs PCT onset timing and SERM dose selection based on the depth and duration of HPG suppression anticipated.
Can Androver tablets be stored and counted accurately across a full cycle and PCT planning period?: The 100-tablet jar format allows straightforward tablet counting throughout the cycle, giving the user a real-time visual of remaining supply and making it easy to set a firm end date before PCT begins. Tablets should be stored at room temperature away from moisture and direct light; Vermodje's blister-sealed production process maintains API stability through the declared shelf life, so tablets remain within specification when stored correctly. (2) angle_used

Manufacturer

Vermodje SRL's international presence reflects a deliberate expansion strategy that places Androver and the broader oral tablet range in distributor networks across European, Baltic, and select non-European markets. Unlike manufacturers who concentrate distribution within a single regional tier, Vermodje's Chișinău-based production facility operates at a scale where documented batch traceability — HPLC content assay, LAL endotoxin screening, and fill-weight uniformity data — travels with each lot through the distribution chain to destination markets. This traceability infrastructure supports the regulatory documentation requirements that international wholesale and pharmacy-adjacent distribution channels impose, giving distributors in multiple jurisdictions a verifiable quality record rather than a certificate of conformity alone. Vermodje's approach to regional availability is product-differentiated: Androver's 100-tablet oral format serves markets where oral androgenic compounds represent the primary accessible product category, and the pack size is calibrated to distribution logistics in those markets.

Product details

Brand	Vermodje
Active ingredient	oxymetholone
Also known as	Anadrol, Anapolon, Oxymetholone, Androver, Vermodje Anadrol
Strength	50 mg
Form	Tabletten
Pack size	100 pieces
Item number	ORA-OXYM-VER-022

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Anapolon 50mg/tab 20 Tablets by Abdi Ibrahim

Lab Tested

Anapolon 50mg/tab 20 Tabletten by Abdi Ibrahim

Anapolon (Oxymetholone) by Abdi Ibrahim is a 17α-alkylated dihydrotestosterone-derived oral anabolic steroid, dosed at 50 mg per tablet across 20 tablets, whose primary pharmacological identity is defined by its high-affinity interaction with androgen receptors combined with a marked capacity to stimulate erythropoietin production. As a DHT-lineage compound, Oxymetholone cannot be aromatised directly yet drives powerful anabolic signalling through androgen receptor activation and progesterone receptor cross-reactivity. Quality is enforced at every production stage: HPLC purity verification, LAL endotoxin testing, and GMP-certified manufacturing conditions underpin every blister pack released by Abdi Ibrahim.

€20.00

Anapolon 50mg/tab 60 Tablets by Balkan Pharmaceuticals

HPLC Verified

Anapolon 50mg/tab 60 Tabletten by Balkan Pharmaceuticals

Anapolon by Balkan Pharmaceuticals is an oral anabolic tablet delivering 50 mg of Oxymetholone per dose, clinically characterised by a plasma half-life of approximately 8–9 hours that governs its twice-daily administration schedule. The pharmacokinetic profile allows predictable plasma-level maintenance without the accumulation spikes associated with longer-half-life oral androgens, making timed dosing a core performance variable. Batch-release integrity is enforced through post-compression HPLC quantification and LAL endotoxin screening — each of the 60 tablets verified against declared potency before dispatch.

€48.00

Pro-Anadrol 50mg/tab 50 Tablets by Beligas Pharmaceuticals

Pharma Grade

Pro-Anadrol 50mg/tab 50 Tabletten by Beligas Pharmaceuticals

Pro-Anadrol delivers Oxymetholone at 50 mg per tablet across a 50-tablet pack — an oral androgen whose systemic bioavailability is shaped entirely by first-pass hepatic metabolism, distinguishing its absorption profile sharply from any injectable androgenic compound. Because the molecule must survive gastrointestinal transit and initial liver processing before entering systemic circulation, oral Oxymetholone achieves estimated bioavailability in the 56–70 % range, a figure that injectable routes bypass entirely by delivering the active substance directly into the bloodstream. Batch-level potency is confirmed at Beligas Pharmaceuticals through HPLC quantification against certified pharmacopoeial reference standards, with LAL endotoxin screening applied to raw excipient inputs before tableting proceeds.

€60.00

OxyTrex 25mg/tab 100 Tablets by Concentrex Labs

Purity Tested

OxyTrex 25mg/tab 100 Tabletten by Concentrex Labs

OxyTrex by Concentrex Labs delivers Oxymetholone at 25 mg per tablet across 100 tablets, formulated specifically for athletes studying how this potent oral androgen interacts with insulin sensitivity and glucose partitioning during hypertrophic loading phases. Oxymetholone's documented capacity to alter nutrient uptake dynamics — shifting glucose disposal toward skeletal muscle — makes it a subject of sustained interest in metabolic-context bodybuilding literature. Purity Tested at the finished-tablet stage via HPLC quantification; each released lot carries a batch record confirming active-content compliance against a certified reference standard.

€60.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00